Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and moni...

Descripción completa

Detalles Bibliográficos
Autores principales: Inzoli, Elena, Aroldi, Andrea, Piazza, Rocco, Gambacorti‐Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Critical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546318/
https://www.ncbi.nlm.nih.gov/pubmed/35384030
http://dx.doi.org/10.1002/ajh.26556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546318/
https://www.ncbi.nlm.nih.gov/pubmed/35384030
http://dx.doi.org/10.1002/ajh.26556

Ejemplares similares